Tonix Pharmaceuticals Holding shares are trading lower. The company announced that it entered into an agreement with the Defense Threat Reduction Agency for $34 million to develop broad-spectrum antiviral TNX-4200.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals Holding shares are trading lower after the company announced a $34 million agreement with the Defense Threat Reduction Agency to develop the broad-spectrum antiviral TNX-4200.
July 01, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tonix Pharmaceuticals Holding shares are trading lower following the announcement of a $34 million agreement with the Defense Threat Reduction Agency to develop the antiviral TNX-4200.
The market reaction to the announcement of the agreement with the Defense Threat Reduction Agency suggests investor concerns about the financial implications or the development risks associated with TNX-4200. This has led to a short-term decline in TNXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100